M. Hailey-Hailey: hSPCA1 Expression and Skin Structure Upon Laser Therapy

March 18, 2024 updated by: Maastricht University Medical Center

Expression of hSPCA1 and Ultrastructural Analysis of the Skin Before and After Laser Therapy in Hailey-Hailey Disease

Hailey-Hailey disease is a genetic acantholytic dermatosis characterized by continuous erosion of the skin that results in a burning, painful sensation and restricts the patient in daily life. This disorder results from a genetic defect in a calcium pump, i.e. the hSPCA1 pump. Calcium pumps are crucial for the processing of cell-cell adhesion proteins such as E-cadherin, part of desmosomes, the major glue between keratinocytes in skin epidermis. Today therapy is mainly focussed on symptom relief and prevention of secondary infection.

Ablative laser therapy is known to result in a speedy healing of the affected skin site within 2 weeks following laser therapy. The fact that the treated skin site remains clear from this acantholytic disorder in the months/years following ablation, regardless the existence of a germline mutation, suggests that an epigenetic modification occurs in the process of wound healing.

Objective: to (1) study the expression of hSPCA1 in keratinocytes before and after laser therapy and (2) verify the loss of acantholysis by immunohistochemistry and electron microscopy of cell-cell adhesions before and after laser therapy

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

11

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Limburg
      • Maastricht, Limburg, Netherlands, 6202 AZ
        • Maastricht University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

1.Inclusion criteria

1.1.Hailey-Hailey patients

Inclusion Criteria:

  • Clinically diagnosed M. Hailey-Hailey as confirmed by histopathology and/or genetic analysis.
  • Indication for ablative laser therapy
  • >18 years old
  • Informed consent

1.2. Patients without Hailey-Hailey disease

  • >18 years old
  • Clinically no symptoms of M. Hailey-Hailey
  • Informed consent

Exclusion Criteria:

  • <18 years old
  • Treatment with tetracyclines, topical hormones or oral retinoids within the last 30 days preceding participation
  • Lack of informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Hailey-Hailey disease

Patients with Hailey Hailey, diagnosis confirmed by histopathology or genetics, with therapy resistant skin lesions suitable for ablative lasertherapy.

Skin biopsy specimens will be taken before and after lasertherapy at three time points.

Before treatment:

Affected skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy Healthy skin within same anatomical region 4 mm punch for immunofluorescence and RNA extraction

Immediately after treatment of the treated area:

2 mm punch for histopathology

Six weeks after treatment:

Treated skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy

2mm punch biopsy of clinically uninvolved skin of the upper arm for electron microscopy

Patients without Hailey-Hailey disease:

2mm punch biopsy of skin of the upper arm for electron microscopy

Skin biopsy:

Tissue samples will be taken by punch biopsy according to the daily routine of the Department of Dermatology of the Maastricht UMC+.

Steps:

  • Skin desinfection with chlorhexidine digluconate 1% solution
  • Local anaesthesia with lidocaine hydrochloride 1%
  • Biopsy specimens are taken with sterile punch device (disposable biopsy punch delivered by kai medical)
  • Biopsy specimens are retrieved with sterile pincer and cut with sterile blade
  • Wound is stitched with a single transcutaneous stich using absorbable suture (vicryl 4.0).
  • Wound will be treated with R/ fusidic acid ointment 3 to 5 times per day for two weeks
  • In the first week after laser therapy the wound will be covered by R/ Urgotull non-adhesive gauze, R/ Cutisoft cotton non-sterile gauze and R/ Klinipress exsupad absorbing bandage.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
hSPCA1 expression
Time Frame: Assessed at time point 0 weeks
Expression of the hSPCA1 calcium pump in keratinocytes before ablative treatment
Assessed at time point 0 weeks
hSPCA1 expression
Time Frame: Assessed 6 weeks after ablative treatment
Expression of the hSPCA1 calcium pump in keratinocytes after ablative treatment
Assessed 6 weeks after ablative treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Expression and localization of desmosomal proteins before and after ablative therapy by immunofluorescence.
Time Frame: At 0 weeks and 6 weeks after ablative therapy
Expression and localization of desmosomal proteins before and after ablative therapy by immunofluorescence.
At 0 weeks and 6 weeks after ablative therapy
Ultrastructure of the skin before and after ablative treatment by electron microscopy and comparison to clinically uninvolved skin and skin of patients without Hailey-Hailey disease.
Time Frame: At 0 weeks and 6 weeks after ablative therapy
Cell-to-cell adhesion and desmosome ultrastructure before and after ablative treatment by electron microscopy and comparison to clinically uninvolved skin and skin of patients without Hailey-Hailey disease.
At 0 weeks and 6 weeks after ablative therapy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Valerie Verstraeten, MD PhD, Maastricht University Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 21, 2018

Primary Completion (Actual)

March 15, 2024

Study Completion (Actual)

March 15, 2024

Study Registration Dates

First Submitted

February 19, 2019

First Submitted That Met QC Criteria

February 20, 2019

First Posted (Actual)

February 21, 2019

Study Record Updates

Last Update Posted (Actual)

March 20, 2024

Last Update Submitted That Met QC Criteria

March 18, 2024

Last Verified

February 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hailey Hailey Disease

Clinical Trials on Skin biopsy

3
Subscribe